A gene on chromosome 20q13 that encodes bone morphogenetic protein-7, which plays a key role in cartilage formation, osteoblast differentiation, renal development and repair, and induces the production of SMAD1.
Stryker stated in its press release that it anticipates commercial launch of OP-1 in the European Union to begin in the third quarter of 2001.
The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the regulatory status of OP-1, status of human clinical trials, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry.
This study confirms the effect of OP-1 in an important model of chronic renal failure.
The study showed that animals treated with OP-1 experienced reduced fibrosis and had less damage to renal tubules where key absorptive events occur, than animals in the ACE inhibitor and control groups.